REG - Synairgen plc - Appointment of New Chairman and Notice of AGM

SynairgenAnnouncement

18/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240918:nRSR5965Ea&default-theme=true

RNS Number : 5965E  Synairgen plc  18 September 2024

 

Synairgen plc

('Synairgen' or the 'Company')

Appointment of New Chairman

Posting of Report and Accounts and Notice of AGM

 

Southampton, UK - 18 September 2024: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces
that Simon Shaw will retire as Chairman at the conclusion of the forthcoming
Annual General Meeting, to be held on 10(th) October 2024.

Mark Parry-Billings, latterly Global Head of Drug Development at Chiesi
Farmaceutici S.p.A ("Chiesi"), will succeed Simon following that meeting.

Dr. Parry-Billings joins Synairgen as an accomplished international biotech
and pharmaceutical executive with a successful track record of more than 30
years heading R&D and leading businesses. Most recently, he held the role
of Global Head of Drug Development at Chiesi, the privately owned global
pharmaceutical company which focuses on innovative therapeutic solutions in
respiratory health, rare diseases and specialty hospital-based care.

Mark has deep expertise in respiratory therapeutics and drug delivery to the
lungs, notably having led multiple novel respiratory assets from early stage
through clinical development to market approvals, with a primary focus on
inhaled drug delivery across respiratory areas including asthma, COPD,
pulmonary arterial hypertension, alpha-1 anti-trypsin deficiency, cystic
fibrosis, bronchiectasis and chronic cough.

Prior to his tenure at Chiesi, Mark led the Canadian clinical-stage
respiratory biotech Topigen Pharmaceuticals as CEO until its acquisition by
Pharmaxis in 2010. Mark also has more than 100 peer-reviewed publications and
conference abstracts spanning activities throughout his pharmaceutical and
academic career to-date.

Simon Shaw, Chairman of the Board of Synairgen, said: "I am delighted to hand
over the reins to Mark, who is a world class inhaled drug development leader.
Synairgen now has both a rigorous development plan for SNG001 and someone with
the optimal experience to guide the company's direction through this next
phase."

Mark Parry-Billings said: "I have followed Synairgen's approach to SNG001 as a
potential broad-spectrum antiviral for a wide range of severe lung infections
for some time and look forward to working with the Board and broader team on
its clinical development in a crucial area of unmet need, whilst acknowledging
Simon's highly effective leadership of the Board to date."

2024 Annual General Meeting

The Company will hold its Annual General Meeting (AGM) at 2:00pm on 10 October
at Numis, 9th Floor, 45 Gresham Street, London EC2V 7BF. The AGM will be held
in person only.

The results of voting on all resolutions at the AGM will be announced via a
Regulatory Information Service and the full results of the voting published on
the Company's website, in the usual way, as soon as practicable after the
conclusion of the AGM.

Annual Report

The Annual Report and Accounts for the year ended 31 December 2023 and Notice
of its 2024 Annual General Meeting have been posted to shareholders. These
documents are available on the Company's website at www.synairgen.com
(http://www.synairgen.com) .

Information required under Rule 17 and Schedule Two, paragraph (g) of the AIM
Rules for Companies ("AIM Rules")

 Full name:                                   Mark Parry-Billings
 Age:                                         60
 Shares held in the Company:                  None
 Current directorships:                       None
 Historic directorships in previous 5 years:  Atopix Therapeutics Limited

                                              Zymenex Holding ApS

On 17 November 2016, Mark Parry-Billings was appointed as a director of Atopix
Therapeutics Limited. The company was dissolved on 2 May 2024 following
members' voluntary liquidation. There were no creditor losses.

On 31 January 2019, Mark Parry-Billings was appointed as a director of Zymenex
Holding ApS. The company was dissolved on 3 December 2020 following voluntary
liquidation. There were no creditor losses.

 

There is no further information to be disclosed in relation to the appointment
pursuant to Rule 17 and Schedule Two, paragraph (g) of the AIM Rules.

 

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Nigel Birks - Life Science Specialist Sales

 

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com (http://www.synairgen.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPURWBUPCPUM